Patient-specific neoantigen peptide–Major Histocompatibility Complex–T-cell receptor interface (NeoAg-MHC-TCR interface)

The patient-specific neoantigen peptide–Major Histocompatibility Complex (MHC)–T-cell receptor (TCR) interface is the fundamental unit of recognition for personalized cancer immunotherapies (Schumacher & Schreiber, 2015, Science). Neoantigens are unique peptides derived from non-synonymous somatic mutations within a patient's tumor that are not found in normal tissues, thereby bypassing central tolerance (Blass & Ott, 2021, Nature Reviews Clinical Oncology). These peptides are presented by the patient's specific HLA alleles (MHC) and recognized by the TCR on the surface of T lymphocytes, initiating a targeted cytotoxic immune response (Yarchoan et al., 2017, NEJM). Therapeutic interventions targeting this interface include personalized vaccines and adoptive TCR-engineered T-cell therapies, which aim to amplify the T-cell response against these tumor-specific markers (Sahin & Türeci, 2018, Science). The specificity of this interaction minimizes damage to healthy cells, although challenges remain regarding the accurate prediction of immunogenic neoepitopes and the potential for tumor escape through MHC downregulation or antigen loss (Gubin et al., 2015, Journal of Clinical Investigation). Modern drug development focuses on optimizing the binding affinity and stability of this tripartite complex to enhance therapeutic efficacy.

Other names

Neoantigen-MHC-TCR complexTumor-specific neoantigen-MHC-TCR interfaceNeoepitope-MHC-TCR interactionPersonalized neoantigen-HLA-TCR interface

Induction of a tumor-specific T-cell response by facilitating the recognition of mutated peptides presented on MHC molecules by T-cell receptors, leading to the expansion of cytotoxic T lymphocytes and targeted destruction of malignant cells.